Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Amino Acid > Cycloserine

Cycloserine

Cycloserine is a cyclic antibiotic derived from Streptomyces orchidaceus with a diverse range of antimicrobial and neurological effects.
It is used primiarly as a second-line tuberculosis treatment, but also shows potential in the management of certain neurological disorders.
Cycloserine functions by inhibiting bacterial cell wall synthesis, leading to cell death.
Reseachers can utilize PubCompare.ai's AI-driven platform to easily identify and compare the best cycloserine protocols and products from literature, preprints, and patents, optimizing reproducibility and accuracy in their cycloserine-based research.

Most cited protocols related to «Cycloserine»

1
Cultivation and Genetic Manipulation of Escherichia coli and Clostridium Species
Cited 19 times

Escherichia coli TOP10 (Invitrogen) and E. coli CA434 [39] (link) were cultured in Luria-Bertani (LB) medium, supplemented with chloramphenicol (25 µg/ml), where appropriate. Routine cultures of C. difficile 630 Δerm[40] (link) and C. difficile R20291 were carried out in BHIS medium (brain heart infusion medium supplemented with 5 mg/ml yeast extract and 0.1% [wt/vol] L-cysteine) [41] (link). C. difficile medium was supplemented with D-cycloserine (250 µg/ml), cefoxitin (8 µg/ml), lincomycin (20 µg/ml), and/or thiamphenicol (15 µg/ml) where appropriate. A defined minimal media [18] (link) was used as uracil-free medium when performing genetic selections. A basic nutritive mannitol broth for growth assays of C. difficile strains were prepared as follows : Proteose peptone no. 2 4% [wt/vol] (BD Diagnostics, USA), sodium phosphate dibasic 0.5%[wt/vol], potassium phosphate monobasic 0.1%[wt/vol], sodium chloride, 0.2% [wt/vol], magnesium sulfate, 0.01% [wt/vol], mannitol, 0.6% [wt/vol] with final pH at +/−7.35. For solid medium, agar was added to a final concentration of 1.0% (wt/vol). Clostridium sporogenes ATCC 15579 was cultivated in TYG media [7] (link). All Clostridium cultures were incubated in an anaerobic workstation at 37°C (Don Whitley, Yorkshire, United Kingdom). Uracil was added at 5 µg/ml, and 5-Fluoroorotic acid (5-FOA) at 2 mg/ml. All reagents, unless noted, were purchased from Sigma-Aldrich.
Ng Y.K., Ehsaan M., Philip S., Collery M.M., Janoir C., Collignon A., Cartman S.T, & Minton N.P. (2013). Expanding the Repertoire of Gene Tools for Precise Manipulation of the Clostridium difficile Genome: Allelic Exchange Using pyrE Alleles. PLoS ONE, 8(2), e56051.
Full text: Click here
Publication 2013
5-fluoroorotic acid Agar Biological Assay Brain Cefoxitin Chloramphenicol Clostridium Clostridium sporogenes Cycloserine Cysteine Diagnosis Escherichia coli Genetic Selection Heart Lincomycin Mannitol potassium phosphate proteose-peptone Sodium Chloride sodium phosphate Strains Sulfate, Magnesium Thiamphenicol Uracil Yeast, Dried
2
D-Cycloserine for Pediatric OCD Treatment
Cited 14 times
Two hundred six youths with a primary OCD diagnosis were enrolled between June 1, 2011, and January 30, 2015, at 2 sites (University of South Florida and Massachusetts General Hospital). Of these, 142 (age range, 7-17 years) were randomized to either D-cycloserine plus CBT or placebo plus CBT. Inclusion criteria were current and primary DSM-IV-TR OCD diagnosis established via clinical assessment and the Schedule for Affective Disorders and Schizophrenia for School-Age Children–Present and Lifetime Version,33 (link) a score of at least 16 on the Children’s Yale-Brown Obsessive Compulsive Scale (CY-BOCS),34 (link) and at least 85 on the full-scale IQ.35 Children were excluded if any of the following criteria were met: (1) They initiated an antidepressant or antipsychotic medication within 12 or 6 weeks, respectively, before enrollment or had an increase in an established antidepressant dosage within 8 weeks before enrollment (6 weeks for antipsychotics). Medications were stable for 8 weeks before enrollment (6 weeks for anti-psychotics) and remained stable throughout treatment. (2) They had epilepsy, renal insufficiency, current or past substance abuse, generally poor physical health, weight less than 22.5 kg, or known D-cycloserine allergy. (3) They were unable to swallow study medication. (4) They had active suicidality or a suicide attempt in the past year. (5) They were pregnant or having unprotected sex (among female participants). (6) They had comorbid psychosis, bipolar disorder, autistic disorder, anorexia nervosa, or non-OCD primary hoarding symptoms.
Storch E.A., Wilhelm S., Sprich S., Henin A., Micco J., Small B.J., McGuire J., Mutch P.J., Lewin A.B., Murphy T.K, & Geller D.A. (2016). Efficacy of Augmentation of Cognitive Behavior Therapy With Weight-Adjusted D-Cycloserine vs Placebo in Pediatric Obsessive-Compulsive Disorder: A Randomized Clinical Trial. JAMA psychiatry, 73(8), 779-788.
Publication 2016
Anorexia Nervosa Antidepressive Agents Antipsychotic Agents Autistic Disorder Bipolar Disorder Child Cycloserine Diagnosis Epilepsy Hypersensitivity Mental Disorders Mood Disorders Pharmaceutical Preparations Physical Examination Placebos Psychotic Disorders Renal Insufficiency Schizophrenia Substance Abuse Suicide Attempt Woman Youth
3
Ethiopia's Multidrug-Resistant TB Program
Cited 9 times
In February 2009, GHC and the Ethiopian FMOH initiated a treatment programme for MDR TB in Ethiopia at St. Peter's Hospital in Addis Ababa. The second site was initiated in September 2010 at the University of Gondar Hospital (UoG) in Gondar, northwestern Ethiopia. Clinical staff involved in programme start-up first received didactic training in Addis Ababa and hands-on training in Cambodia from GHC and ongoing clinical mentorship. This group formed the key participants in the Ethiopian MDR Technical Working Group.
All patients with MDR TB, defined as having evidence of resistance to isoniazid and rifampicin by phenotypic drug-susceptibility testing or genotypic resistance by a line probe assay (GenoType MTBDRplus V.2.0, HAIN Life Science, Nehren, Germany), were eligible to receive treatment. Additionally, patients with rifampicin-monoresistance or those with clinically presumed MDR TB, based on multiple treatment failures despite directly observed therapy (DOT), or those who were close contacts of patients with MDR TB, were also eligible for treatment. A standardised, second-line drug (SLD) regimen was administered, consisting of (1) at least three oral agents to which the patient was presumed to have susceptibility (eg, levofloxacin, ethionamide, cycloserine or para-aminosalicyclic acid (PAS)), (2) pyrazinamide and (3) an aminoglycoside (amikacin or kanamycin) or polypeptide (capreomycin) injectable agent. Injectables were maintained for a minimum of 8 months based on clinical, microbiological and radiographic evolution, and ultimate treatment duration was a minimum of 18 months after bacteriological conversion.
Most patients were hospitalised at the initiation of therapy in accordance with national standards until they smear converted and were clinically stable, followed by transition to the ambulatory setting. A subset of healthier patients was initiated on therapy as outpatients beginning in 2010. After discharge from the hospital, patients returned to the hospital outpatient clinic on a monthly basis and visited health centres in their proximity for daily drug administration and observation. Monthly sputum samples were collected for both inpatients and outpatients for smear and mycobacterial culture.
Family treatment supporters were trained for drug adherence monitoring, and those patients living within Addis Ababa and Gondar were visited monthly at home by a dedicated outpatient team. All patients received a monthly food basket. After assessment of the patient's living conditions, those found to be vulnerable due to extreme poverty were provided economic assistance for transport, additional food and house rent if needed throughout therapy. Patients who were initiated on therapy as outpatients were followed by the GHC outpatient team, including roving nurses who provided them with daily injections of the injectable agent (5–6 days per week). All patients were screened for HIV upon enrolment. Patients who were HIV-infected were offered antiretroviral therapy (ART) regardless of CD4 cell count if not on ART prior to enrolment, or were continued on ART, if on this treatment already.
Meressa D., Hurtado R.M., Andrews J.R., Diro E., Abato K., Daniel T., Prasad P., Prasad R., Fekade B., Tedla Y., Yusuf H., Tadesse M., Tefera D., Ashenafi A., Desta G., Aderaye G., Olson K., Thim S, & Goldfeld A.E. (2015). Achieving high treatment success for multidrug-resistant TB in Africa: initiation and scale-up of MDR TB care in Ethiopia—an observational cohort study. Thorax, 70(12), 1181-1188.
Publication 2015
Acids Amikacin Aminoglycosides Biological Assay Biological Evolution Capreomycin Cell Therapy Cycloserine Directly Observed Therapy Ethionamide Food Food Additives Genotype Injectables Inpatient Isoniazid Kanamycin Levofloxacin Mentorships Mycobacterium Nurses Outpatients Patient Discharge Patients Pharmaceutical Preparations Phenotype Polypeptides Pyrazinamide Rifampin Sputum Susceptibility, Disease Treatment Protocols X-Rays, Diagnostic
4
Quantifying Gut Microbiota in Chickens with C. jejuni
Cited 7 times
C. jejuni were enumerated in intestinal contents of ileum, caecum and faeces from 5 chickens per isolator at each sampling day. The samples (approximately 3 g) were homogenized, and serially diluted in 10-fold in phosphate buffered saline and plated on modified blood free charcoal cefoperazone deoxycholate agar base (Oxoid, CM0739). The plates were incubated with C. jejuni specific growth supplements at 42 °C for 48 h under microaerobic conditions (5% O2, 5% CO2, 5% H2, and 85% N2). Enterobacteria (E. coli and lactose negative enterobacteria) were enumerated on MacConkey agar (Merck, Darmstadt, Germany, 1.05465) incubated aerobically at 37 °C for 24 h as described by Engberg et al. [37 (link)]. Lactic acid bacteria (LAB) and Clostridium perfringens were counted respectively on De Man Rogosa Sharpe agar (Merck, 1.10660) incubated anaerobically at 37 °C for 48 h and tryptose sulphite cycloserine plates (TSC-Agar, Merck, 1.11072) incubated anaerobically at 37 °C for 24 h. Enterococci were counted on Slanetz and Bartely plates (Merck, 1.05289) after aerobic incubation at 37 °C for 48 h. The results are presented as microbial number (CFU/g) in ileal/caecal or faecal material. The detection limit was 10 2 bacteria/g. During the experiment, water samples were collected from the drinkers in the isolators and the antimicrobial effect of AgNP on C. jejuni was investigated in in vitro using the plate count method.
Vadalasetty K.P., Lauridsen C., Engberg R.M., Vadalasetty R., Kutwin M., Chwalibog A, & Sawosz E. (2018). Influence of silver nanoparticles on growth and health of broiler chickens after infection with Campylobacter jejuni. BMC Veterinary Research, 14, 1.
Full text: Click here
Publication 2018
Agar Bacteria Bacteria, Aerobic Blood Cecum Cefoperazone Charcoal Chickens Clostridium perfringens Cycloserine Deoxycholate Dietary Supplements Enterobacteriaceae Enterococcus Escherichia coli Feces Hartnup Disease Ileum Intestinal Contents Lactobacillales Lactose Microbicides Phosphates Saline Solution Sulfites tryptose
5
Propagating C. difficile Strains
Cited 7 times
C. difficile strains, outlined in Table 1, were propagated either in TY broth without thioglycolate [5] (link) or on BHI agar. Cultures were incubated at 37 °C in an anaerobic environment composed of 80% nitrogen, 10% hydrogen and 10% carbon dioxide. Escherichia coli was routinely grown in LB broth or on LB agar. E. coli strain CA434 (HB101 carrying R702) was used as the conjugation donor throughout. NEB5α (New England Biolabs) was used for cloning and plasmid propagation. Growth media was supplemented with chloramphenicol (15 μg/ml), thiamphenicol (15 μg/ml) or cycloserine (250 μg/ml) as appropriate.
Kirk J.A, & Fagan R.P. (2016). Heat shock increases conjugation efficiency in Clostridium difficile. Anaerobe, 42, 1-5.
Full text: Click here
Publication 2016
Agar Carbon dioxide Chloramphenicol Culture Media Cycloserine Escherichia coli Hydrogen Nitrogen Plasmids Strains Thiamphenicol Thioglycolates Tissue Donors

Most recents protocols related to «Cycloserine»

1
Clostridioides difficile Spore Preparation

Clostridioides difficile spore stocks were generated as described previously [19 (link)]. Briefly, C difficile strains were grown in 2 mL Columbia broth overnight at 37°C anaerobically. The 2-mL inoculum was then added to 40 mL Clospore media. The culture was incubated anaerobically at 37°C for 5–7 days. After the incubation, spores were harvested by centrifuging the culture at 3200 rpm for 20 minutes at 4°C, then resuspending in cold sterile water. After washing the spores at least 3 times, the spore stocks were stored at 4°C in sterile water. The stocks were heat treated at 65°C for 20 minutes to eliminate any remaining vegetative cells. The concentration of spores in each stock was determined by serially diluting the stocks in anaerobic phosphate-buffered saline (PBS) and plating on brain-heart infusion (BHI) agar supplemented with 1% sodium taurocholate. Once the colony-forming units (CFU)/mL of each stock was determined, the infection inoculum was prepared by diluting the appropriate C difficile strain spore stock to the appropriate concentration. Animals received 100 µL of inoculum each via oral gavage.
To determine C difficile colonization in infected animals, cecal contents were resuspended and serially diluted in reduced PBS. Serial dilutions were plated on BHI agar supplemented with 1% sodium taurocholate, 1 mg/mL cycloserine, and 0.032 mg/mL cefoxitin (Sigma, St. Louis, MO), then incubated at 37°C overnight in an anaerobic chamber. Bacterial burden was normalized to cecal content sample weight.
Simpson M., Bilverstone T., Leslie J., Donlan A., Uddin M.J., Petri W.A., Marin N., Kuehne S., Minton N.P, & Petri WA J.r. (2023). Clostridioides difficile Binary Toxin Binding Component Increases Virulence in a Hamster Model. Open Forum Infectious Diseases, 10(3), ofad040.
Publication 2023
Agar Animals Bacteria Brain Cecum Cefoxitin Cells Clostridioides Common Cold Cycloserine Heart Infection Phosphates Saline Solution Spores Sterility, Reproductive Strains Taurocholic Acid, Monosodium Salt Technique, Dilution Tube Feeding
2
Anaerobic Culturing of Clostridia Strains
The strains used in this study are listed in Table S3. Strains were cultured on brain heart infusion (BHI) agar or broth (Oxoid) at 37°C in an anaerobic chamber (Biomerieux, Marcy l’Etoile, France) (v/v: 80% N2, 10% H2, 10% CO2). When necessary, the medium was supplemented with cycloserine (250 mg.mL−1), thiamphenicol (15 mg.mL−1 to select KO strains or 7.5 mg.mL−1 to maintain the plasmid pMTL007-hbd), or erythromycin (5 mg.mL−1). Escherichia coli TOP10 strain was used for cloning and plasmid propagation. E. coli HB101 (RP4) strain was used as the conjugative donor for developing the clostridia KO strains. E. coli strains were cultured aerobically at 37°C in Luria–Bertani agar or broth, and when needed, the medium was supplemented with ampicillin (100 mg.mL−1) or chloramphenicol (25 mg.mL−1).
Ferraris L., Balvay A., Bellet D., Delannoy J., Maudet C., Larcher T., Rozé J.C., Philippe C., Meylheuc T., Butel M.J., Rabot S, & Aires J. (2023). Neonatal necrotizing enterocolitis: Clostridium butyricum and Clostridium neonatale fermentation metabolism and enteropathogenicity. Gut Microbes, 15(1), 2172666.
Full text: Click here
Publication 2023
Agar Ampicillin Brain Chloramphenicol Clostridium Cycloserine Erythromycin Escherichia coli Heart Plasmids Strains Thiamphenicol Tissue Donors
3
Inactivation of hbd Gene in Clostridia
The oligonucleotides and plasmids used in this study are listed in Table S1 and S4, respectively. The mobile group II intron system was used as described previously to inactivate the hbd.34 (link),48 (link) The algorithm available on the TargeTron Design Site (http://www.clostron.com/clostron2.php) was used to identify the intron insertion site within hbd (position 414) and design primers to retarget the group II intron in hbd (c-hbd-414|415s-IBS, c-hbd-414|415s-EBS1d, and c-hbd-414|415s-EBS2). These primers were used with EBS universal primers and intron template DNA to generate a DNA fragment by overlap PCR as recommended by manufacturers. The PCR product was purified using QIAquick PCR Purification Kit (Qiagen, Courtaboeuf, France) and digested by BsrGI and HindIII restriction enzymes. Plasmid pMTL007C-E2-hbd was developed by ligating (T4 DNA ligase) (Sigma Aldrich Chimie, Saint-Quentin-Fallavier, France) the digested PCR product and pMTL007C-E2 digested with BsrGI/HindIII and purified with QIAEX II Gel Extraction kit (Qiagen). The ligation mixture was introduced into E. coli TOP10 by electroporation. After extracting the plasmid (QIAprep Spin Miniprep kit, Qiagen) and amplifying the insert by FastStart High Fidelity PCR System (Sigma Aldrich Chimie,) with primers pMTLCE2seqF and pMTLseqR, the cloned insert was verified by DNA sequencing using the same primers (Genewiz, Takeley, UK). The plasmid pMTL007C-E2-hbd was transformed into the conjugative donor E. coli HB101 (RP4) and transferred into the C. butyricum 1002 and C. neonatale 250.09 strains via conjugation. The transconjugants were selected on BHI agar supplemented with cycloserine and thiamphenicol. Inactivation of hbd was verified by screening transconjugants for erythromycin resistance and thiamphenicol sensitivity, and the resultant strains were named CbuCB1002-hbd415s::CT and Cne205.09-hbd415s::CT. Further, genomic DNA was extracted (InstaGene Matrix Kit) (Bio-Rad, Marnes-la-Coquette, France) and subjected to PCR using primers flanking hbd (hbdF and hbdR) to verify the intron insertion into the correct target gene. Moreover, the presence of the ermB was confirmed by PCR using primers RAMFCE2 and RAMRCE2, and the orientation of insertion was verified by PCR with a combination of hbdF, hbdR, and EBS Universal primers.
Ferraris L., Balvay A., Bellet D., Delannoy J., Maudet C., Larcher T., Rozé J.C., Philippe C., Meylheuc T., Butel M.J., Rabot S, & Aires J. (2023). Neonatal necrotizing enterocolitis: Clostridium butyricum and Clostridium neonatale fermentation metabolism and enteropathogenicity. Gut Microbes, 15(1), 2172666.
Full text: Click here
Publication 2023
Agar Cycloserine DNA, A-Form DNA Restriction Enzymes Electroporation Erythromycin Escherichia coli Gene Insertion Genome Hypersensitivity Introns Ligation Oligonucleotide Primers Oligonucleotides Plasmids Strains T4 DNA Ligase Thiamphenicol Tissue Donors
4
Comparative Plant Growth Experiments
Seeds of Arabidopsis Col-0, as well as T-DNA insertion lines, analyzed in this study were provided by the Nottingham Arabidopsis Stock Centre (University of Nottingham, UK) or the Arabidopsis Biological Resource Center (University of Ohio, Columbus, OH, USA). Seedling germination experiments were conducted on solid growth media consisting of ½ MS basal salts with 1% sucrose and 1% phytoagar (Duchefa Biochemie, Haarlem, The Netherlands), including further conditional additions (e.g., D-Cycloserine, amino acid azides). These plates were grown for up to 10 days in growth chambers under a long daylight regime (16 h light, 8 h dark) at 18–20 °C. Adult plants were grown for four weeks on soil in a greenhouse with long daylight regime (16 h light, 8 h dark) at 20–22 °C. For experiments with N. benthamiana, the leaves of adult plants were also grown on soil for four weeks in a greenhouse. Protonemal cultures of P. patens were kindly provided by Andreas Hiltbrunner (University of Freiburg, Germany) and were cultivated as described before [12 (link)].
Tran X., Keskin E., Winkler P., Braun M, & Kolukisaoglu Ü. (2023). The Chloroplast Envelope of Angiosperms Contains a Peptidoglycan Layer. Cells, 12(4), 563.
Full text: Click here
Publication 2023
Adult Amino Acids Arabidopsis Azides Biopharmaceuticals Culture Media Cycloserine Germination Light Plant Embryos Plant Leaves Plants Salts Sucrose T-DNA
5
Necrotic Enteritis Induction in Broiler Chickens
The NE disease induction model was performed as previously described [33 (link),48 (link)]. Briefly, a total of 36 commercial 1-day-old Arbor Acres broiler chickens (Beijing Arbor Acres Poultry Breeding Co. Ltd., Beijing, China) were divided into four experimental groups, including a non-challenged control, a challenged control group, and two challenged groups supplemented with either AMG (4 mg/kg, 8 mg/kg or 20 mg/kg body weight) or amoxicillin (1 mg/kg body weight). From day 0 to day 11, all broiler chickens received a control diet with no antibiotics. On day 12 the feed was changed to a mixture of 50% wheat-based and 50% fish meals. On the evening of the 13th day, the feed was withdrawn, and each bird was orally challenged with 1.0 mL of C. perfringens culture (109 CFU/mL). From day 18 to day 20, birds were treated with AMG for three days. On day 21, chickens were euthanized with inhaled carbon dioxide gas, and their small intestines (duodenum to ileum) were examined for gross necrotic lesions. C. perfringens was recovered from the intestines of killed birds by culturing on Tryptose Sulfite Cycloserine Agar Base (TSC, Bridge Technology Co., Ltd., Beijing, China).
Liu Y., Zhu J., Qu S., Shen J, & Zhu K. (2023). Plant-Derived Xanthones against Clostridial Enteric Infections. Antibiotics, 12(2), 232.
Full text: Click here
Publication 2023
Agar Amoxicillin Antibiotics, Antitubercular Aves Body Weight Carbon dioxide Chickens Clostridium perfringens Cycloserine Diet Duodenum Fishes Fowls, Domestic Ileum Intestines Intestines, Small Necrosis Sulfites Triticum aestivum tryptose

Top products related to «Cycloserine»

1
D cycloserine by Merck Group
Sourced in United States, United Kingdom, Australia
D-cycloserine is a laboratory reagent used in various scientific research applications. It is a cyclic analogue of the amino acid D-alanine. D-cycloserine has applications in the study of microbial metabolism, enzymatic processes, and biochemical pathways. Its core function is to serve as a research tool for scientific investigations, without interpretation of intended use.
2
Cefoxitin by Thermo Fisher Scientific
Sourced in United Kingdom, United States, France
Cefoxitin is a cephalosporin antibiotic used in the laboratory setting. It functions as a bactericidal agent, inhibiting the synthesis of the bacterial cell wall. Cefoxitin has a broad spectrum of activity against both gram-positive and gram-negative bacteria.
3
Chloramphenicol by Merck Group
Sourced in United States, Germany, France, United Kingdom, Italy, China, Australia, Israel, Switzerland, Spain, India, Sao Tome and Principe, Brazil, Canada, Belgium, Czechia, Mexico, Poland, Ireland
Chloramphenicol is a bacteriostatic antibiotic that inhibits protein synthesis in bacteria. It is commonly used in microbiology laboratories for selective cultivation and identification of bacterial species.
4
Cycloserine by Merck Group
Sourced in United States
Cycloserine is a laboratory chemical used in various research applications. It functions as an antibiotic and inhibits bacterial cell wall synthesis. Cycloserine is commonly utilized in microbiological studies, biochemical assays, and other scientific investigations.
5
L cycloserine by Merck Group
L-cycloserine is a type of laboratory equipment used in various scientific research and analytical applications. It is a chemical compound that functions as a reagent or analytical tool. The core function of L-cycloserine is to serve as a specific and selective inhibitor of certain enzymes or biological processes, which can be utilized in various experimental and analytical procedures. A detailed description of its intended use or application is not provided to maintain an unbiased and factual approach.
6
Isoniazid by Merck Group
Sourced in United States, Germany, United Kingdom, Poland, Sao Tome and Principe, India
Isoniazid is a chemical compound used as a laboratory reagent. It functions as an analytical standard for the identification and quantification of isoniazid in various samples. The compound is widely utilized in analytical chemistry and pharmaceutical research applications.
7
Anaerobic chamber by Coy Laboratory Products
Sourced in United States
The Anaerobic Chamber is a laboratory equipment designed to provide a controlled, oxygen-free environment for various applications that require an anaerobic atmosphere. It maintains a low-oxygen, high-nitrogen or carbon dioxide atmosphere to support the growth and handling of anaerobic organisms or to perform experiments and procedures that require an anaerobic environment.
8
Genbag anaer by bioMérieux
Sourced in France
GENbag anaer is a laboratory equipment product designed for the cultivation of anaerobic microorganisms. It provides an oxygen-free environment suitable for the growth of anaerobic bacteria and other anaerobic organisms.
9
Ethambutol by Merck Group
Sourced in United States, Japan
Ethambutol is a laboratory equipment product manufactured by Merck Group. It is a chemical compound with the formula C10H24N2O2. Ethambutol is used in laboratory settings for various research and analytical applications.
10
Rifampicin by Merck Group
Sourced in United States, Germany, France, United Kingdom, Switzerland, Macao, Sao Tome and Principe, Ireland, India, Australia, Sweden, China, Italy, Spain, Czechia, Netherlands
Rifampicin is a lab equipment product manufactured by Merck Group. It is a chemical compound used in various laboratory applications and research purposes.

More about "Cycloserine"

Cycloserine, a cyclic antibiotic derived from the Streptomyces orchidaceus bacterium, has a diverse range of antimicrobial and neurological effects.
It is primarily used as a second-line treatment for tuberculosis, but also shows potential in managing certain neurological disorders.
Cycloserine, also known as D-cycloserine or L-cycloserine, works by inhibiting bacterial cell wall synthesis, leading to cell death.
This mechanism of action makes it an effective antimicrobial agent against a variety of microorganisms, including Mycobacterium tuberculosis, the causative agent of tuberculosis.
In addition to its antimicrobial properties, cycloserine has also been studied for its potential use in the management of neurological conditions, such as obsessive-compulsive disorder (OCD) and social anxiety disorder.
Researchers have found that cycloserine, a partial agonist of the N-methyl-D-aspartate (NMDA) receptor, can modulate glutamatergic neurotransmission, which plays a crucial role in the pathophysiology of these disorders.
To optimize cycloserine-based research, researchers can utilize PubCompare.ai's AI-driven platform.
This platform enables researchers to easily identify and compare the best cycloserine protocols and products from literature, preprints, and patents, ensuring enhanced reproducibility and accuracy in their research.
By leveraging PubCompare.ai's cutting-edge tools, researchers can identify the most effective cycloserine-based treatments and protocols, ultimately advancing their understanding and application of this versatile compound.
Researchers may also explore the use of other related antimicrobial agents, such as cefoxitin, chloramphenicol, ethambutol, and rifampicin, which have been used in combination with cycloserine for the treatment of tuberculosis.
Additionally, the use of anaerobic chambers, such as the GENbag anaer, can be beneficial in culturing and studying anaerobic microorganisms, which may be relevant to cycloserine-based research.